Skip to content
Vanta Bioscience logo

Vanta Bioscience

540729 BSE
₹20.39

Close ·

P/E
Not meaningful: loss-making over the last twelve months
View as Markdown
MCP
Close 30 Oct 2026 ₹20.39 −7.30 −26.4% 1Y
Start ₹27.69

Key Fundamentals

SMEHealthcare ServicesHealthcare

Price-based figures at the close · TTM

ROCE
1.19%
Debt to Equity
1.80
EPS (TTM)
−₹3.90
Book Value
₹29.77
Market Cap
—
P/E (TTM)
Not meaningful: loss-making over the last twelve months
P/B
0.68
ROE
0.70%
Dividend Yield
0.00%
EBITDA
₹1.02 Cr
52W High
₹29.00
52W Low
₹14.71

Key Insights

Strengths

2
  • Company has reduced debt.
  • Stock is trading at 0.69 times its book value

Weaknesses

6
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -28.6% over past five years.
  • Company has a low return on equity of -15.6% over last 3 years.
  • Company might be capitalizing the interest cost
  • Company has high debtors of 513 days.
  • Working capital days have increased from -636 days to 435 days

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1171
OscillatorsNeutral171
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
44.51
Neutral
MACD (12,26,9)
−0.44
Bearish
SMA (50)
21.31
Bearish
SMA (200)
22.73
Bearish

As of

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
5Y−28.62%
3Y−32.16%
1Y−7.14%

Net profit

Net profit growth by window
5Y−24.55%
3YTurned to profit
1YTurned to profit

Operating cash flow

Operating cash flow growth by window
5YTurned negative
3YOutflow widened by ₹4.59 Cr
1YOutflow widened by ₹2.81 Cr

Operating margin· change in pp

Operating margin growth by window
5Y+15.82 pp
3Y+97.03 pp
1Y+272.88 pp

Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.

Revenue by year

Revenue by year, ₹ crore
Mar 2019₹12.08 Cr
Mar 2020₹13.75 Cr
Mar 2021₹9.82 Cr
Mar 2022₹9.40 Cr
Mar 2023₹5.83 Cr
Mar 2024₹9.72 Cr
Mar 2025₹1.96 Cr
Mar 2026₹1.82 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2019₹0.70 Cr
Mar 2020₹1.01 Cr
Mar 2021₹0.45 Cr
Mar 2022₹0.14 Cr
Mar 2023−₹10.44 Cr
Mar 2024−₹8.61 Cr
Mar 2025−₹13.29 Cr
Mar 2026₹0.11 Cr

Half-yearly Results

₹ Cr
540729 half-yearly results, ₹ crore
Particulars Mar 2020Sep 2020Mar 2021Sep 2021Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026
Sales
6.81
5.28
4.76
5.38
4.31
2.82
3.45
6.18
3.55
1.03
0.33
0.3
1.51
Expenses
4.61
3.5
2.58
3.89
2.33
3.37
5.3
4.12
4.3
1.42
2.01
0.67
0.13
Operating Profit
2.2
1.78
2.18
1.49
1.98
−0.55
−1.85
2.06
−0.75
−0.39
−1.68
−0.37
1.38
OPM %
32.31%
33.71%
45.8%
27.7%
45.94%
−19.5%
−53.62%
33.33%
−21.13%
−37.86%
−509.09%
−123.33%
91.39%
Other Income
0.11
0
0.03
0.02
0.4
0.01
0.68
0.03
0.08
0.04
0.04
0
0.16
Interest
0.98
1.01
1.13
1.14
1.2
2.48
3.4
2.85
2.9
2.14
−0.06
0.88
−0.11
Depreciation
0.78
0.61
0.65
0.66
0.66
1.31
1.36
1.54
2.95
1.69
−0.17
0.61
−0.23
PBT
0.55
0.16
0.43
−0.29
0.52
−4.33
−5.93
−2.3
−6.52
−4.18
−1.41
−1.86
1.88
Tax %
16.36%
68.75%
9.3%
−106.9%
13.46%
2.08%
1.52%
−0.87%
−3.07%
−1.2%
−2.13%
−2.69%
−2.66%
Net Profit
0.46
0.06
0.39
0.02
0.07
−2.56
−3.92
−0.54
−1.78
−2.07
−1.37
−1.82
1.93
EPS (₹)
0.73
0.1
0.62
0.03
0.11
−4.06
−6.21
−0.86
−2.82
−3.28
−2.17
−2.56
2.71

Profit & Loss

₹ Cr
540729 profit and loss, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
12.08
13.75
9.82
9.4
5.83
9.72
1.96
1.82
Expenses
8.81
9.38
5.87
5.93
8.22
8.41
6.21
0.8
Operating Profit
3.27
4.37
3.95
3.47
−2.39
1.31
−4.25
1.02
OPM %
27.07%
31.78%
40.22%
36.91%
−40.99%
13.48%
−216.84%
56.04%
Other Income
0.23
0.11
0.03
0.42
0.69
0.11
0.11
0.16
Interest
1.69
1.95
2.14
2.35
5.89
5.75
4.07
0.78
Depreciation
0.71
1.19
1.25
1.32
2.67
4.5
4.42
0.39
PBT
1.1
1.34
0.59
0.22
−10.26
−8.83
−12.63
0.01
Tax %
36.36%
24.63%
23.73%
40.91%
1.75%
−2.49%
5.23%
−900%
Net Profit
0.7
1.01
0.45
0.14
−10.44
−8.61
−13.29
0.11
EPS (₹)
1.11
1.58
0.71
0.14
−10.27
−3.68
−7.56
0.15
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%

Balance Sheet

₹ Cr
540729 balance sheet, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
6.31
6.31
6.31
6.31
6.31
6.31
6.31
7.11
Reserves
15.94
17.16
17.61
17.7
11.2
8.89
4.11
14.06
Borrowings
13.25
17.37
35.97
44.86
57.16
60.96
70.09
38.08
Other Liabilities
3.51
7.74
9.74
12.53
10.04
9.24
5.37
6.85
Total Liabilities
39.01
48.58
69.63
81.4
84.71
85.4
85.88
66.1
Fixed Assets
17.9
20.76
29.39
36.12
57.22
54.15
55.5
48.08
CWIP
3.7
7
19.34
28.47
10.6
12.53
13.47
0
Investments
1.95
0
0
0
0
0
0
3
Other Assets
15.46
20.82
20.9
16.81
16.89
18.72
16.91
15.02
Total Assets
39.01
48.58
69.63
81.4
84.71
85.4
85.88
66.1

Cash Flow

₹ Cr
540729 cash flow, annual, ₹ crore
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−1.04
2.34
6.97
5.28
−0.63
2.68
−2.41
−5.22
Investing
−5.73
−7.59
−22.3
−17.24
−5.91
−3.31
−6.69
−6.87
Financing
9.94
2.17
17.78
9.53
6.41
0.69
9.16
12.08
Net Cash Flow
3.18
−3.07
2.46
−2.43
−0.13
0.06
0.06
−0.01
Free Cash Flow
−3.52
−5.01
−15.23
−11.9
−6.54
−0.63
−9.1
−12.09
CFO/OP
−32
54
176
152
26
205
57
−512

Ratios

540729 financial ratios, annual
Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
47.14
36.9
74.71
43.88
123
118
466
513
Inventory Days
—
—
—
—
—
—
2,400
—
Days Payable
—
—
—
—
—
—
1,821
—
Cash Conversion Cycle
47.14
36.9
74.71
43.88
123
118
1,044
513
Working Capital Days
261
260
91.06
−135
−163
−217
−2,127
435
ROCE %
—
8.35%
5.21%
3.77%
−5.82%
−4.16%
−11.58%
1.19%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Vanta Bioscience insights

57 extracted metrics across FY17–FY26.

Shareholding Pattern

As of Sep 2026

  • Promoters 72.81%
  • Public 24.36%
  • Others 2.84%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Vanta Bioscience

What does Vanta Bioscience Ltd do?
Incorporated in 2016, Vanta Bioscience Ltd is a full-service preclinical contract research organisation.
Where is Vanta Bioscience Ltd (VANTABIO) listed?
Vanta Bioscience Ltd trades under code 540729 on the BSE.
Which sector does Vanta Bioscience Ltd belong to?
Vanta Bioscience Ltd is classified under the Healthcare sector, in the Healthcare Technology industry.
What is the 52-week high and low of Vanta Bioscience Ltd?
Over the last 52 weeks Vanta Bioscience Ltd has traded between ₹14.71 and ₹29 as of 30 Oct 2026.
What is the Return on Equity (ROE) of Vanta Bioscience Ltd?
Vanta Bioscience Ltd reported a return on equity of 0.70%. Its debt-to-equity ratio is 1.80.

Company Information

Incorporated in 2016, Vanta Bioscience Ltd is a full-service preclinical contract research organisation.

Website vantabio.com
Listed 6 Oct 2017
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/540729.md for Vanta Bioscience Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Hospital & Healthcare Services stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month